UAB Researchers Discover why Brain Neurons in Parkinson's Disease Stop Benefiting from Levodopa
The mechanism may be therapeutic target to prevent or reverse dyskinesia
Though the drug levodopa (L-DOPA) can dramatically improve Parkinson’s disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition – involuntary repetitive, rapid and jerky movements. This abnormal motor behavior appears only while taking L-DOPA, a it stops if the drug is stopped. However, if L-DOPA is taken again, even many months later, it quickly re-emerges. In research to prevent this side effect and extend the usefulness of L-DOPA – which is the most effective drug treatment for Parkinson’s disease – University of Alabama at Birmingham researchers have uncovered an essential mechanism of this long-term memory for L-DOPA-induced-dyskinesia, or LID. To read more, click here.
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.
13th Head & Neck Cancer Symposium
April 6-7, 2017; Amsterdam, The Netherlands
Endoscopic and Endoscope-Assisted Neurosurgery Under FULL HD Visualization
April 6-7, 2017; Germany